Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance.
Nafise GhalandariHubertina J M J CrijnsJorieke E H BergmanRadboud J E M DolhainEugène P van PuijenbroekJohanna M W HazesPublished in: British journal of clinical pharmacology (2022)
No special safety signal was identified regarding the occurrence of CMs after exposure to abatacept (n = 64), anakinra (n = 20), belimumab (n = 93), ixekizumab (n = 29), rituximab (n = 57), secukinumab (n = 128), tocilizumab (n = 124) and ustekinumab (n = 215). Regarding observed CCAs in the vedolizumab group (n = 113), no firm conclusions can be made based on available information.
Keyphrases
- rheumatoid arthritis
- ankylosing spondylitis
- rheumatoid arthritis patients
- systemic lupus erythematosus
- disease activity
- diffuse large b cell lymphoma
- risk assessment
- ulcerative colitis
- patients with inflammatory bowel disease
- juvenile idiopathic arthritis
- health information
- chronic lymphocytic leukemia
- hodgkin lymphoma